GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Cyclically Adjusted PB Ratio

MedMira (MedMira) Cyclically Adjusted PB Ratio : (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MedMira Cyclically Adjusted PB Ratio Historical Data

The historical data trend for MedMira's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Cyclically Adjusted PB Ratio Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedMira's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, MedMira's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MedMira's Cyclically Adjusted PB Ratio falls into.



MedMira Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

MedMira's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, MedMira's adjusted Book Value per Share data for the three months ended in Jan. 2024 was:

Adj_Book=Book Value per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.017/125.0724*125.0724
=-0.017

Current CPI (Jan. 2024) = 125.0724.

MedMira Quarterly Data

Book Value per Share CPI Adj_Book
201404 -0.012 98.920 -0.015
201407 -0.012 99.315 -0.015
201410 -0.011 99.473 -0.014
201501 -0.012 98.209 -0.015
201504 -0.011 99.710 -0.014
201507 -0.011 100.579 -0.014
201510 -0.004 100.500 -0.005
201601 -0.005 100.184 -0.006
201604 -0.007 101.370 -0.009
201607 -0.009 101.844 -0.011
201610 -0.009 102.002 -0.011
201701 -0.009 102.318 -0.011
201704 -0.010 103.029 -0.012
201707 -0.011 103.029 -0.013
201710 -0.012 103.424 -0.015
201801 -0.013 104.056 -0.016
201804 -0.013 105.320 -0.015
201807 -0.013 106.110 -0.015
201810 -0.014 105.952 -0.017
201901 -0.014 105.557 -0.017
201904 -0.015 107.453 -0.017
201907 -0.016 108.243 -0.018
201910 -0.016 107.927 -0.019
202001 -0.017 108.085 -0.020
202004 -0.017 107.216 -0.020
202007 -0.018 108.401 -0.021
202010 -0.017 108.638 -0.020
202101 -0.018 109.192 -0.021
202104 -0.019 110.851 -0.021
202107 -0.019 112.431 -0.021
202110 -0.020 113.695 -0.022
202201 -0.013 114.801 -0.014
202204 -0.014 118.357 -0.015
202207 -0.014 120.964 -0.014
202210 -0.014 121.517 -0.014
202301 -0.014 121.596 -0.014
202304 -0.015 123.571 -0.015
202307 -0.016 124.914 -0.016
202310 -0.017 125.310 -0.017
202401 -0.017 125.072 -0.017

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MedMira  (OTCPK:MMIRF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


MedMira Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of MedMira's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Industry
Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Reports Third Quarter Results FY2022

By GlobeNewswire GlobeNewswire 06-30-2022

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018